Strong vaccine-driven quarterly figures for Pfizer

By: Miguel A. Rodriguez

11:06, 05 May 2021

Pfizer, one of the pandemic’s pharma company stars due to the COVID-19 vaccine developed with BioNTech, reported better-than-expected Q1 2021 figures

The company reported an adjusted EPS of 93 cents, ahead of the 77 cents consensus. At the same time, Wall Street was looking for $13.51 billion in revenue, but the actual figures came in at $ $14.58 billion. Moreover, revenue from oncology, internal medicine, hospital, and rare disease units increased by double digits in the past three months. Its immunology and inflammation unit generated approximately $1 billion in sales – a 9% increase compared to what in reported during the same time last year.

Along with the financial report came the news that it plans to file for full US approval of its COVID-19 vaccine at the end of May. If Pfizer receives FDA’s approval, it will sell the vaccine shot directly to consumers. Moreover, the company expects to apply for a EUA (Emergency Use Authorization) for a booster shot that potentially could protect people against virus’ new variants during the second half of July. In September and November, it will apply for authorization for the vaccine used on toddlers, younger children, and infants, respectively.

For the future, Pfizer expects its full-year sales to reach $26 billion from the vaccine, revising upwards of its previous $15 billion forecast. During Q1, it had sales of $3.5 billion. By the end of July, it plans to deliver 300 million doses.

After the news hit the wires, Pfizer stock price went up 1.4%.



Share this article

The information presented herein is prepared by and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only.Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience, or current financial situation. 

Key Way Markets Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.